CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.03 Billion CNY | -48.69% |
| 2022 | -1.36 Billion CNY | -171.6% |
| 2021 | 1.91 Billion CNY | 534.14% |
| 2020 | -440.32 Million CNY | -117.9% |
| 2019 | -202.07 Million CNY | -45.82% |
| 2018 | -138.57 Million CNY | -117.22% |
| 2017 | -63.79 Million CNY | -21.09% |
| 2016 | -52.68 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -75.58 Million CNY | 56.78% |
| 2024 Q1 | -174.88 Million CNY | 81.73% |
| 2023 Q2 | -1.15 Billion CNY | -497.92% |
| 2023 Q1 | -192.34 Million CNY | 83.03% |
| 2023 FY | -2.03 Billion CNY | -48.69% |
| 2023 Q4 | -957.15 Million CNY | -239.79% |
| 2023 Q3 | 684.71 Million CNY | 159.54% |
| 2022 Q3 | -36.01 Million CNY | 88.73% |
| 2022 Q4 | -1.13 Billion CNY | -3046.6% |
| 2022 Q1 | 112.98 Million CNY | -81.45% |
| 2022 Q2 | -319.42 Million CNY | -382.73% |
| 2022 FY | -1.36 Billion CNY | -171.6% |
| 2021 Q4 | 609.14 Million CNY | 54.31% |
| 2021 FY | 1.91 Billion CNY | 534.14% |
| 2021 Q1 | -48.58 Million CNY | 84.52% |
| 2021 Q3 | 394.75 Million CNY | -52.37% |
| 2021 Q2 | 828.75 Million CNY | 1805.68% |
| 2020 Q3 | -75.43 Million CNY | -19.02% |
| 2020 FY | -440.32 Million CNY | -117.9% |
| 2020 Q2 | -63.38 Million CNY | -62.34% |
| 2020 Q1 | -39.04 Million CNY | -57.55% |
| 2020 Q4 | -313.9 Million CNY | -316.12% |
| 2019 Q3 | -44.56 Million CNY | -119.61% |
| 2019 FY | -202.07 Million CNY | -45.82% |
| 2019 Q2 | -20.29 Million CNY | 58.5% |
| 2019 Q1 | -48.89 Million CNY | -6.43% |
| 2019 Q4 | -24.78 Million CNY | 44.39% |
| 2018 Q1 | -29.62 Million CNY | 14.32% |
| 2018 Q3 | -45.93 Million CNY | -55.09% |
| 2018 Q4 | -45.93 Million CNY | 0.0% |
| 2018 FY | -138.57 Million CNY | -117.22% |
| 2018 Q2 | -29.62 Million CNY | 0.0% |
| 2017 Q2 | -16.11 Million CNY | 0.0% |
| 2017 Q4 | -34.57 Million CNY | 0.0% |
| 2017 FY | -63.79 Million CNY | -21.09% |
| 2017 Q1 | -16.11 Million CNY | 0.0% |
| 2016 Q1 | -12.46 Million CNY | 0.0% |
| 2016 FY | -52.68 Million CNY | 0.0% |
| 2016 Q4 | -16.11 Million CNY | 0.0% |
| 2016 Q2 | -12.46 Million CNY | 0.0% |
| 2015 Q4 | -12.46 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 1523.085% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 176.413% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | -24834.844% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 5078.43% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | -3800.086% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 5746.696% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 755.813% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | -2981.461% |
| SSY Group Limited | 1.63 Billion HKD | 224.18% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 1268.268% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 710.935% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 116.755% |